Fragment 176-191

Also known as HGH Fragment 176-191, HGH Frag 176-191, Frag 176-191, Lipolytic fragment of hGH

The C-terminal lipolytic fragment of human growth hormone studied for fat metabolism without GH's growth or glucose effects.

Molecular weight~1817 g/mol (commonly cited; note vendor figures often conflate it with AOD-9604)

Half-life~30 minutes (estimated; some sources cite up to 2–3 hours).

CategoryMetabolic

Typical use cases

✓ Fat loss / lipolysis research✓ Body-composition studies✓ Metabolic research

Dosing guidelines

StartingResearch protocols often begin around 250 mcg/day subcutaneous.

Maintenance~250–500 mcg/day, sometimes split into 2 doses (e.g. morning fasted and pre-workout).

Max (studied)Upper bounds near ~1000 mcg/day appear in some protocols, but human safety data at any dose are limited — treat as a hedge, not a recommendation.

Titration

Typically flat-dosed; some protocols ramp from a lower starting dose to assess tolerance.

Reconstitution

5 mg vial: ~2 mL bacteriostatic water yields ~2500 mcg/mL (0.1 mL = 250 mcg).

Injection sites

Subcutaneous into abdominal fat (rotate sites); often timed to fasted states in research protocols.

Storage & handling

Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).

Side effects

Injection-site redness or irritation Mild · Common
Transient hunger or lethargy Mild · Uncommon
Mild water retention Mild · Rare

Research summary

Fragment 176-191 corresponds to the last 16 amino acids of human growth hormone, the region carrying GH's lipolytic (fat-mobilizing) activity while excluding the IGF-1/diabetogenic effects of the full molecule; proposed mechanisms include stimulation of hormone-sensitive lipase and β3-adrenergic signaling in adipocytes. Evidence is largely preclinical (rodent/in vitro); the better-studied clinical relative is AOD-9604, a tyrosine-modified analog of this fragment, so data on the two are not interchangeable. Rigorous human efficacy/safety data on the unmodified fragment are thin. Educational only — not medical advice.

Key references

Heffernan et al., Endocrinology (2001) — lipolytic action of the hGH 176-191 region and its analog
Ng & Bornstein, Horm. Metab. Res. — identification of the C-terminal lipolytic domain of hGH

Related compounds

Where to buy

🛍 Core Peptides Third-party tested ↗

These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.

Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.

Track Fragment 176-191 in DoseForge

Log doses, rotate sites, watch your progress — free.

Get the app